Selfish brain and neuroprogression in bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 66-71

  Mansur, Rodrigo B ^a,b   Cha, Danielle S ^a,b   Asevedo, Elson ^a,b   McIntyre, Roger S ^a,b   Brietzke, Elisa ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bipolar disorder; Brain energy metabolism; Metabolism; Neuroprogression

Indexed keywords

CYTOKINE; DOPAMINE; FREE RADICAL; GLUTAMIC ACID; NEUROTROPHIN;

BIPOLAR DISORDER; BRAIN METABOLISM; CELL LOSS; DISEASE ASSOCIATION; ENERGY METABOLISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MANIA; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; MORTALITY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; REVIEW; SELFISH BRAIN;

EID: 84872367932     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.004     Document Type: Review

References (84)

1. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41(6):523-529.
2. Ashton C.H., Moore P.B. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand 2011, 124(4):250-261.
3. Attwell D., Laughlin S.B. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001, 21(10):1133-1145.
4. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009, 12(6):805-822.
5. Bechdolf A., Nelson B., Cotton S.M., Chanen A., Thompson A., Kettle J., et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. J Affect Disord 2010, 127(1-3):316-320.
6. Benard G., Massa F., Puente N., Lourenco J., Bellocchio L., Soria-Gomez E., et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 2012, 15(4):558-564.
7. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009, 12(4):441-445.
8. Berk M., Conus P., Kapczinski F., Andreazza A.C., Yucel M., Wood S.J., et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010, 193(Suppl. 4):S36-S40.
9. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35(3):804-817.
10. Berk M., Malhi G.S., Hallam K., Gama C.S., Dodd S., Andreazza A.C., et al. Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord 2009, 114(1-3):1-13.
11. Bermudez-Silva F.J., Cardinal P., Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2012, 26(1):114-124.
12. Birkenaes A.B., Opjordsmoen S., Brunborg C., Engh J.A., Jonsdottir H., Ringen P.A., et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry 2007, 68(6):917-923.
13. Bosy-Westphal A., Kossel E., Goele K., Later W., Hitze B., Settler U., et al. Contribution of individual organ mass loss to weight loss-associated decline in resting energy expenditure. Am J Clin Nutr 2009, 90(4):993-1001.
14. Brietzke E., Mansur R.B., Soczynska J.K., Kapczinski F., Bressan R.A., McIntyre R.S. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord 2012, 140:82-91.
15. Cataldo A.M., McPhie D.L., Lange N.T., Punzell S., Elmiligy S., Ye N.Z., et al. Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 2010, 177(2):575-585.
16. Cervantes P., Gelber S., Kin F.N., Nair V.N., Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 2001, 26(5):411-416.
17. Chaput J.P., Drapeau V., Poirier P., Teasdale N., Tremblay A. Glycemic instability and spontaneous energy intake: association with knowledge-based work. Psychosom Med 2008, 70(7):797-804.
18. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011, 29(3):311-324.
19. Cowansage K.K., LeDoux J.E., Monfils M.H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol 2010, 3(1):12-29.
20. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398(3):215-219.
21. Czepielewski L, Daruy-Filho L, Brietzke E, Grassi-Oliveira R. Bipolar Disorder and Metabolic Syndrome: A Systematic Review. Revista Brasileira de Psiquiatria. in press.
22. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29(8):1558-1572.
23. Daban C., Vieta E., Mackin P., Young A.H. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005, 28(2):469-480.
24. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009, 60(2):77-84.
25. Fernandes B.S., Gama C.S., Cereser K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45(8):995-1004.
26. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008, 69(4):514-519.
27. Gans R.O. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 2006, 90(4):573-591.
28. Gjedde A. Blood-barrier glucose transfer. Physiology and Pharmacology of the Blood-brain Barrier 1992, 65-115. Springer, Berlin. W.B. Bradbury (Ed.).
29. Golden S.H., Lazo M., Carnethon M., Bertoni A.G., Schreiner P.J., Diez Roux A.V., et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008, 299(23):2751-2759.
30. Goldstein B.I., Liu S.M., Zivkovic N., Schaffer A., Chien L.C., Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord 2011, 13(4):387-395.
31. Gurpegui M., Martinez-Ortega J.M., Gutierrez-Rojas L., Rivero J., Rojas C., Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37(1):169-175.
32. Hamer M., Batty G.D., Kivimaki M. Haemoglobin A1c, fasting glucose and future risk of elevated depressive symptoms over 2years of follow-up in the English Longitudinal Study of Ageing. Psychol Med 2011, 41(9):1889-1896.
33. Hamer M., Batty G.D., Kivimaki M. Risk of future depression in people who are obese but metabolically healthy: the English longitudinal study of ageing. Mol Psychiatry 2012, 17(9):940-945.
34. Hamer M., Molloy G.J., de Oliveira C., Demakakos P. Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: the English Longitudinal Study of Ageing. Psychoneuroendocrinology 2009, 34(7):1050-1055.
35. Harris J.J., Jolivet R., Attwell D. Synaptic energy use and supply. Neuron 2012, 75(5):762-777.
36. Hitze B., Hubold C., van Dyken R., Schlichting K., Lehnert H., Entringer S., et al. How the selfish brain organizes its supply and demand. Front Neuroenerg 2010, 2(7).
37. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005, 14(2):241-253.
38. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Brietzke E., Vazquez G.H., Vieta E., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1366-1371.
39. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32(4):675-692.
40. Katsel P., Byne W., Roussos P., Tan W., Siever L., Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 2011, 36(6):1171-1177.
41. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010, 12(4):404-413.
42. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62(6):593-602.
43. Kim B., Kim S., McIntyre R.S., Park H.J., Kim S.Y., Joo Y.H. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Invest 2009, 6(2):78-84.
44. Lucas M., Mekary R., Pan A., Mirzaei F., O'Reilly E.J., Willett W.C., et al. Relation between clinical depression risk and physical activity and time spent watching television in older women: a 10-year prospective follow-up study. Am J Epidemiol 2011, 174(9):1017-1027.
45. Madsen P.L., Hasselbalch S.G., Hagemann L.P., Olsen K.S., Bulow J., Holm S., et al. Persistent resetting of the cerebral oxygen/glucose uptake ratio by brain activation: evidence obtained with the Kety-Schmidt technique. J Cereb Blood Flow Metab 1995, 15(3):485-491.
46. Maina G., Salvi V., Vitalucci A., D'Ambrosio V., Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord 2008, 110(1-2):149-155.
47. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012, 13(5):293-307.
48. Mansur R.B., Brietzke E. The "selfish brain" hypothesis for metabolic abnormalities in bipolar disorder and schizophrenia. Trends Psychiatry Psychother 2012, 34(3):121-128.
49. Mathers C.D., Lopez A.D., Murray C.J.L. The burden of disease and mortality by condition: data, methods, and results for 2001 2006.
50. McElroy S.L. Diagnosing and treating comorbid (complicated) bipolar disorder. J Clin Psychiatry 2004, 65(Suppl. 15):35-44.
51. McElroy S.L., Keck P.E. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep 2012, 14(6):650-658.
52. McIntyre R.S. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. J Clin Psychiatry 2009, 70(Suppl. 3):5-11.
53. McIntyre R.S., Danilewitz M., Liauw S.S., Kemp D.E., Nguyen H.T., Kahn L.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010, 126(3):366-387.
54. McIntyre R.S., Nguyen H.T., Soczynska J.K., Lourenco M.T., Woldeyohannes H.O., Konarski J.Z. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci 2008, 10(2):203-213.
55. McIntyre R.S., Rosenbluth M., Ramasubbu R., Bond D.J., Taylor V.H., Beaulieu S., et al. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Ann Clin Psychiatry 2012, 24(2):163-169.
56. Mikkelsen S.S., Tolstrup J.S., Flachs E.M., Mortensen E.L., Schnohr P., Flensborg-Madsen T. A cohort study of leisure time physical activity and depression. Prev Med 2010, 51(6):471-475.
57. Minocci D., Massei J., Martino A., Milianti M., Piz L., Di Bello D., et al. Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. J Affect Disord 2011, 134(1-3):427-430.
58. Mitrakou A., Ryan C., Veneman T., Mokan M., Jenssen T., Kiss I., et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991, 260(1 Pt 1):E67-E74.
59. Monteleone P., Bifulco M., Maina G., Tortorella A., Gazzerro P., Proto M.C., et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010, 61(5):400-404.
60. Neves-Pereira M., Mundo E., Muglia P., King N., Macciardi F., Kennedy J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002, 71(3):651-655.
61. Perala J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsa E., Pirkola S., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007, 64(1):19-28.
62. Perron B.E., Howard M.O., Nienhuis J.K., Bauer M.S., Woodward A.T., Kilbourne A.M. Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 2009, 70(10):1407-1415.
63. Peters A., Schweiger U., Pellerin L., Hubold C., Oltmanns K.M., Conrad M., et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004, 28(2):143-180.
64. Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fan J.B., Schaffner S.F., et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 2010, 15(8):810-815.
65. Post R.M., Fleming J., Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res 2012, 46(5):561-573.
66. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6(3):219-233.
67. Sanchez-Villegas A., Field A.E., O'Reilly E.J., Fava M., Gortmaker S., Kawachi I., et al. Perceived and actual obesity in childhood and adolescence and risk of adult depression. J Epidemiol Community Health 2012, 67(1):81-86.
68. Schmider J., Lammers C.H., Gotthardt U., Dettling M., Holsboer F., Heuser I.J. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995, 38(12):797-802.
69. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14(3):235-237.
70. Shugart Y.Y., Chen L., Day I.N., Lewis S.J., Timpson N.J., Yuan W., et al. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur J Hum Genet 2009, 17(8):1050-1055.
71. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008, 10(5):607-616.
72. Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., Liauw S.S., Alsuwaidan M., Yim C.Y., et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med 2011, 13(2):93-116.
73. Steiner J., Bernstein H.G., Bielau H., Berndt A., Brisch R., Mawrin C., et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007, 8(2).
74. Taylor M., Bressan R.A., Pan Neto P., Brietzke E. Early intervention for bipolar disorder: current imperatives, future directions. Rev Bras Psiquiatr 2011, 33:S213-S217.
75. Tohen M., Hennen J., Zarate C.M., Baldessarini R.J., Strakowski S.M., Stoll A.L., et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000, 157(2):220-228.
76. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., Stertz L., Goi J., Chiarani F., et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009, 452(2):111-113.
77. Unger T.J., Calderon G.A., Bradley L.C., Sena-Esteves M., Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 2007, 27(52):14265-14274.
78. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001, 55(5):597-610.
79. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Goncalves C.L., Cardoso M.R., et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 2010, 44(14):903-909.
80. Vieta E., Martinez-De-Osaba M.J., Colom F., Martinez-Aran A., Benabarre A., Gasto C. Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med 1999, 29(4):971-978.
81. Ximenes da Silva A., Lavialle F., Gendrot G., Guesnet P., Alessandri J.M., Lavialle M. Glucose transport and utilization are altered in the brain of rats deficient in n-3 polyunsaturated fatty acids. J Neurochem 2002, 81(6):1328-1337.
82. Xu B., Goulding E.H., Zang K., Cepoi D., Cone R.D., Jones K.R., et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003, 6(7):736-742.
83. Yim C.Y., Soczynska J.K., Kennedy S.H., Woldeyohannes H.O., Brietzke E., McIntyre R.S. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry 2012, 27(3):223-228.
84. Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev 2004, 44(3):273-282.